PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 139 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $57,379 | -45.1% | 3,440 | -9.1% | 0.04% | -43.5% |
| Q2 2023 | $104,569 | -55.8% | 3,786 | -63.2% | 0.06% | -52.3% |
| Q1 2023 | $236,578 | +52.3% | 10,286 | -27.7% | 0.13% | +60.5% |
| Q4 2022 | $155,304 | +29.4% | 14,235 | -0.0% | 0.08% | +68.8% |
| Q3 2022 | $120,000 | +7.1% | 14,237 | +0.8% | 0.05% | +14.3% |
| Q2 2022 | $112,000 | -9.7% | 14,129 | +170.9% | 0.04% | -23.6% |
| Q1 2022 | $124,000 | -34.4% | 5,216 | -5.5% | 0.06% | -22.5% |
| Q4 2021 | $189,000 | +105.4% | 5,521 | +6.8% | 0.07% | +77.5% |
| Q3 2021 | $92,000 | -62.3% | 5,170 | -5.0% | 0.04% | -60.0% |
| Q2 2021 | $244,000 | -34.4% | 5,441 | -62.1% | 0.10% | -36.3% |
| Q1 2021 | $372,000 | +31.0% | 14,346 | +1.7% | 0.16% | +33.1% |
| Q4 2020 | $284,000 | -23.7% | 14,102 | -26.0% | 0.12% | -39.5% |
| Q3 2020 | $372,000 | -2.6% | 19,048 | -12.0% | 0.20% | +7.7% |
| Q2 2020 | $382,000 | – | 21,639 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |